Adolor Corporation
From Wikipedia, the free encyclopedia
Adolor Corporation (NASDAQ: ADLR) is a biopharmaceutical company specializing in the discovery, development and commercialization of prescription pain management products.
Adolor has two lead product candidates in development: Entereg (alvimopan) for the management of the gastrointestinal side effects associated with opioid use; and, Delta opioid receptor agonists for a variety of pain indications. Adolor and GlaxoSmithKline are collaborating in the worldwide development and commercialization of Entereg in multiple indications. The drug is being reviewed by the Food and Drug Administration, and the process is expected to be completed in May 2008.[1] Adolor and Pfizer are collaborating in the worldwide development and commercialization of two Delta agonists for pain.[2] Adolor also has a number of discovery research programs focused on the identification of novel compounds for the treatment of pain.
Adolor has is headquarters in in Exton, PA.
[edit] References
- ^ "Adolor narrows loss on falling revenue", The Philadelphia Inquirer, 2008-02-29. Retrieved on 2008-03-21.
- ^ "Pfizer To Acquire Encysive For About $195 Mln Cash; Plans Late Stage Trial For PAH Therapy", RTT News, 2008-02-20. Retrieved on 2008-03-21.
[edit] External links
This United States corporation or company article is a stub. You can help Wikipedia by expanding it.
